A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy

Who May Qualify: - \<2 years of age at the time of willing to sign a consent form - Confirmed diagnosis of 5q-autosomal recessive SMA, including genetic confirmation of homozygous deletion or compound heterozygosity predictive of loss of function of the Survival of Motor Neuron 1 (SMN1) gene - Confirmed presence of two SMN2 gene copies as documented through laboratory testing - Administration of onasemnogene abeparvovec pre-symptomatically or post-symptomatically - Has received onasemnogene abeparvovec for SMA no less than 13 weeks, but not more than months 30 weeks, prior to enrollment - If treated with risdiplam prior to onasemnogene abeparvovec, risdiplam treatment must not have exceeded 3 weeks and must be discontinued 1 day prior to onasemnogene abeparvovec administration - Has, in the opinion of the investigator, not experienced clinically significant decline in function from the time of onasemnogene abeparvovec administration Who Should NOT Join This Trial: - Previous or current enrolment in investigational study prior to initiation of study treatment - Any unresolved standard-of-care laboratory abnormalities per the onasemnogene abeparvovec prescribing information - Concomitant or previous administration of an SMN2-targeting antisense oligonucleotide - Concomitant or previous use of an anti-myostatin agent - Participants requiring invasive ventilation or tracheostomy - Participants requiring awake non-invasive ventilation or with awake hypoxemia (Arterial Oxygen Saturation \[SaO2\] \<95%) with or without ventilator support - Presence of feeding tube and an OrSAT score of 0 - Hospitalization for pulmonary event within the last 2 months, or any planned hospitalization at the time of screening - Any major illness requiring hospitalization within 1 month before the screening examination or any febrile illness within 1 week prior to screening and up to first dose administration. Always talk to your doctor about whether this trial is right for you.